Welcome to our dedicated page for Ctt Pharmaceutic news (Ticker: CTTH), a resource for investors and traders seeking the latest updates and insights on Ctt Pharmaceutic stock.
News for CTT Pharmaceutical Holdings, Inc. (OTCQB: CTTH) centers on its development of micelle-based thin film oral drug delivery systems and the company’s progress across scientific, regulatory, and capital markets milestones. This page aggregates press releases and third-party coverage that reflect how CTT’s technology and corporate strategy are evolving over time.
Readers can find updates on scientific publications, including peer-reviewed articles that describe how micellar nanotechnology combined with oral dissolvable strips may improve delivery and bioavailability of active compounds. CTT also reports on grant-related developments with agencies such as the National Science Foundation and National Institutes of Health, particularly around its patented fast dissolving nicotine strips and smoke-free low-dose dissolvable strip concepts for smoking cessation.
Corporate and capital markets news includes items such as uplistings to the OTCQB Market, changes to authorized share counts, and the filing of a Form S-1 registration statement with the U.S. Securities and Exchange Commission. These updates provide context on CTT’s efforts to align with reporting standards, adjust its capital structure, and secure access to financing through mechanisms like an Equity Line of Credit.
Regulatory and intellectual property developments, including notifications of intention to grant additional European patent claims and plans for further patent filings, are also covered. Investors, researchers, and other interested readers can use this news stream to follow how CTT links its thin film oral delivery platform to smoking cessation, diabetes-related drugs, and broader pharmaceutical, therapeutic, and nutraceutical applications.
CTT Pharmaceutical Holdings (OTCQB:CTTH) filed a Form S-1 with the SEC on December 30, 2025 to transition to fully reporting status and strengthen corporate transparency. The company advanced an initial $3,000,000 equity line and signed an agreement with RH2 Equity Partners to increase that facility to $10,000,000 to support commercialization and scaling of future product lines. CTT reported a peer-reviewed publication approval on micelle-enhanced thin film oral delivery systems and plans a perspective article and a comprehensive research paper in 2026. Management cites progress on manufacturing readiness and regulatory alignment as it prepares for commercial deployment.
CTT Pharma (OTCQB:CTTH) announced on December 16, 2025 that a peer‑reviewed paper was published in the journal Drug Delivery and Therapeutics by Dr. Katharine Cole and Dr. Pankaj Modi.
The review describes how micellar nanotechnology combined with an oral dissolvable strip delivery system can improve delivery and bioavailability of active therapeutic compounds. The company says the article is the first comprehensive scientific review on this combined approach.
The publication is available in the company's Scientific Publications section at www.cttpharmaceuticals.com and the company indicates additional peer‑reviewed articles will be added as available.
CTT Pharmaceutical Holdings (OTCQB:CTTH) CEO Ryan Khouri provided a shareholder update regarding the company's ongoing grant applications and smoking cessation initiatives. The company has submitted applications for NIH and NSF grants before the January 6th deadline, with responses expected in April or May 2025. The review process is scheduled to begin in March.
The NIH grant would enable Johns Hopkins University to conduct clinical trials of CTT's innovative smoke-free low dose dissolvable strip, potentially creating the first new oral smoking cessation product in 40 years. The company has strengthened its team by adding two experienced grant specialists.
Khouri previously spoke at the FDA Headquarters in Maryland in October 2024 at an FDA and NIH event on Advancing Smoking Cessation Technology, receiving positive feedback. A conference call with shareholders is planned for April 2025, with the specific date to be announced.
CTT Pharmaceutical Holdings (OTCQB:CTTH) has successfully uplisted to the OTCQB Market effective March 9, 2025, trading under the ticker symbol 'CTTH'. The company's CEO is scheduled to release a shareholder update on Wednesday, March 12, 2025.
CTT Pharmaceutical Holdings (OTCQB:CTTH) has received approval from OTC Markets Group for uplisting its common shares to the OTCQB Market, effective March 10, 2025. The company will continue trading under the symbol 'CTTH'.
The uplisting to OTCQB, a premier marketplace for early-stage pharmaceutical companies developing new technology, is expected to enhance trading liquidity and provide a more streamlined trading experience for U.S. shareholders. Companies listed on OTCQB must maintain current reporting status and undergo annual PCAOB audits.
The company plans to make formal announcements regarding the uplisting on March 10, 2025, followed by a CEO news release to shareholders on March 12, 2025.
CTT Pharmaceutical Holdings (OTC PINK:CTTH) announced it anticipates receiving notification regarding its uplisting status to the OTCQB market during the week of March 3, 2025. The company stated it will keep shareholders informed of any developments regarding this potential market transition.
CTT Pharmaceutical Holdings (OTC PINK:CTTH) has received notification of an intention to grant from the European Patent Office (EPO) for additional claims to their original European Patent. The company already received an intention to grant for their micelle delivery technology but chose to further define and strengthen their patent specifically for diabetes-related drugs.
With the patent for the diabetes drug Liraglutide having expired, CTT plans to explore opportunities to utilize their micelle technology for this medication. The company believes their technology could provide an enhanced drug delivery system for pharmaceutical companies with current patented diabetes drugs and those in development.
CTT is actively strengthening their patents in both the United States and Europe and intends to file provisional patents in 2025 to further protect their technology. The company has committed to updating shareholders on additional provisional patents once filed and how they will support future development.
CTT Pharmaceutical Holdings (OTC:CTTH) has advanced past the initial round in its application for a National Science Foundation (NSF) grant for its patented fast-dissolving nicotine strips. The company is now among a few thousand remaining applicants from an initial pool of over 12,000. CTT expects to receive a response by late April.
The company's technology aims to address a significant public health issue, as cited by WHO statistics showing tobacco kills over 8 million people annually worldwide. According to CDC data, cigarette smoking causes more than 480,000 deaths yearly in the United States, representing nearly 1 in 5 deaths.
CEO Ryan Khouri highlighted that CTT's advancement in the NSF application process demonstrates the potential value of their technology in the tobacco industry. The company notes that there are currently no fast-dissolving, low-dose nicotine strips available in the market.
CTT Pharmaceuticals Holdings (OTC PINK:CTTH) has appointed Dr. Katherine Cole as an Independent Director. Dr. Cole brings extensive experience in biomedical research and academic leadership, including a Ph.D. in Pathology from the University of Maryland School of Medicine and three years at the National Cancer Institute (NIH) studying anti-cancer mechanisms.
Dr. Cole's credentials include positions as a biomedical scientist, professor, and vice Provost and Dean across four universities. She has authored twenty-two peer-reviewed papers and holds two patents related to a human liver cell line. Her research has been supported by grants from the National Science Foundation and the Howard Hughes Medical Institute.
CTT Pharmaceuticals Holdings (OTC:CTTH) has announced a significant reduction in its authorized share count, cutting it by 150 million shares from 300 million to 150 million shares. The change has been officially filed with the Delaware Division of Corporations and recorded by the company's stock issuer.
The company states this adjustment reflects its commitment to optimizing its capital structure and creating long-term shareholder value. Additionally, CTT is pursuing approval for an uplisting to the OTCQB market.